The truth is, however, that Pfizer is simply so big that any one new product isn’t really going to move the needle. The bigger issue is simply that large value stocks, like Pfizer, have been largely out of favor lately. People are flocking to growth and tech stocks instead. At some point, that will flip and PFE stock will take off.
Full Answer
Should you sell Pfizer stock now?
May 14, 2021 · It's possible that Pfizer's COVID-19 vaccine revenue will continue to be strong, maybe not at 2021 levels, but in 2022, 2023, and beyond, it's very possible anyway that the company could make a lot...
Why is Pfizer stock declining?
Apr 08, 2021 · It's actually up just a little under 5% right now. Pfizer stock is up all of 0.4%. ... Part of it is going to be how prevalent COVID-19 is in a few …
Should I Buy More Pfizer?
Dec 17, 2020 · Pfizer ( PFE-1.28%) received great news last Thursday that an advisory committee to the U.S. Food and Drug Administration (FDA) overwhelmingly recommended Emergency Use Authorization (EUA) for its ...
Is Pfizer a good stock?
Feb 23, 2021 · One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth,...
There are several potential reasons why investors didn't cheer the companies' great news more loudly
We've known for a while that the COVID-19 vaccine developed by Pfizer ( PFE -2.89% ) and BioNTech ( BNTX 5.62% ) was highly effective in individuals ages 16 and up. The two partners recently announced an impressive 100% efficacy for the vaccine in children between the ages of 12 and 15.
NYSE: PFE
Keith Speights: Pfizer and BioNTech announced results from their phase 3 study and this study showed 100% efficacy for their COVID vaccine, BNT162b2. Kids ages 12 through 15. So the companies plan to move pretty quickly to file for Emergency Use Authorization.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Why is Pfizer down?
Another reason Pfizer has been down is that they've had some clinical setbacks. They really had high hopes for breast cancer drug Ibrance, and early breast cancer setting, and had a couple of clinical studies that didn't pan out so well, and so that's been another negative impact on the stock.
Why is Pfizer weighing down?
One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth, earnings growth, and that's been a big problem.
When did Keith start writing for the Fool?
There are two main reasons. At least one of them, though, isn't a problem anymore. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics.
